ClinicalTrials.gg
CompletedNCT06742840Updated Sep 3, 2025

A Multiple Ascending Dose Trial of HRS-2129 in Healthy Subjects

A Phase 1 interventional study of HRS-2129 and HRS-2129 placebo in Pain, sponsored by Shandong Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-03.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Pain by Jiangsu HengRui Medicine Co., Ltd. — none open to participants now, none under way, none of them phase 3. Pain · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
15th of 15
23 · median 96
Started
2024
with 1 other
Phase 1
7 of 15
none open now
Registered
13th of 15
by date

Among the 15 studies in Pain by Jiangsu HengRui Medicine Co., Ltd., this one is the 15th largest by enrollment, is one of 2 that started in 2024, is one of 7 in phase 1, and was the 13th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

None of the 15 studies in Pain by Jiangsu HengRui Medicine Co., Ltd. is open now. The open studies under Pain, anywhere →

Where they have run

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Pain by Jiangsu HengRui Medicine Co., Ltd. as a file.
02

Study summary

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-2129 in healthy subjects.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18 to 55 years old (inclusive);
  2. Body weight: ≥ 50 kg for male and ≥ 45 kg for female, : 19.0 \~ 28.0 kg/m2 (inclusive);
  3. Subject has no plan to give a birth, donate sperm or eggs from signing the form to 6 months after last dose;
  4. Female subjects: non-pregnant or non-lactating;
  5. The skin to receive pain stimuli has no wound or derma disease;
  6. Subject who is willing to accept pain test;
  7. Subject who voluntarily signs the informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Subject who suffers from clinical acute and chronic diseases of circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry and metabolic abnormalities;
  2. Subject with a history of torsade de pointes, symptomatic or multigenic or frequent or require medical treatment arrhythmia, or personal or family history of short syndrome or long QT syndrome;
  3. Subject with a history of allergies to the IMP or its , or subject with allergic constitution;
  4. Subject who underwent major surgery within 6 months prior to screening, or received surgery that may significantly affect the pharmacokinetics or safety evaluation of the IMP, or who plans to undergo surgery during the study period;
  5. Subject with a medication history that inhibits or induces liver metabolism of drug has been used within 1 month before administration;
  6. Subject with vaccinated within 1 month prior to screening or plan to be vaccinated during the study;
  7. Subject who used any drugs or health products (including Chinese herbal medicines) within 7 half-lives or 14 days (whichever is longer) before administration, or who plans to receive other drug treatments during the study;
  8. Subject who has participated in clinical trials and received experimental drugs within 3 months before screening, or plans to participate in other clinical trials during this study;
  9. Donate blood/blood loss ≥ 400 mL within 3 months before screening;
  10. Subject who smoked more than 5 cigarettes per day on average within 3 months before screening;
  11. Drink more than 14 units of alcohol per week on average;
  12. Drink excessive tea, coffee or caffeinated beverages within 3 months before screening;
  13. Consume special food (such as grapefruit, grapefruit juice or food/drink containing grapefruit juice, chocolate, tobacco, alcohol, caffeine and other food or drink) within 48 hours before administration;
  14. Subject who has special requirements for diet and cannot follow a unified diet;
  15. Subject with clinical significant abnormalities in medical examination;
  16. Subject with positive tests for surface antigen, virus antibody, syphilis or antibody;
  17. Subject with a history of drug abuse or with a positive result for drug abuse test;
  18. Alcohol test result is positive;
  19. Subject who has difficulty in swallowing, or venous blood collection, or who cannot tolerate venipuncture, or who has a history of fainting of needle or blood;
  20. Subject who is judged to have suicidal ideation or suicidal behavior by mental state assessment;
  21. Subject may not be able to complete the study due to other reasons or the investigators considers that he is not suitable for inclusion.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    HRS-2129 experimental group

    Drug: HRS-2129

  • Placebo comparator
    HRS-2129 placebo group

    Drug: HRS-2129 placebo

Interventions

  • HRS-2129.

  • DrugHRS-2129 placebo

    HRS-2129 placebo.

06

What researchers measure

Primary outcomes

  1. The incidence and severity of adverse events (AEs)

    Time frame: From ICF signing date to Day 39.

  2. The incidence and severity of adverse events (AEs)

    Time frame: From ICF signing date to Day 41.

Secondary outcomes

  1. Cold Pain detection threshold for the Thermode Cold Test

    Time frame: Day 1 to Day 12.

  2. Cold Pain detection threshold for the Thermode Cold Test

    Time frame: Day 1 to Day 15.

  3. Heat Pain detection threshold for the Thermode Heat Test

    Time frame: Day 1 to Day 12.

  4. Heat Pain detection threshold for the Thermode Heat Test

    Time frame: Day 1 to Day 15.

  5. Pain tolerance time for the Cold Pain Test

    Time frame: Day 1 to Day 12.

  6. Pain tolerance time for the Cold Pain Test

    Time frame: Day 1 to Day 15.

  7. Number of participants with clinically meaningful findings in Columbia Suicide Severity Rating Scale (C-SSRS) Responses

    Time frame: From ICF signing date to Day 13.

  8. Number of participants with clinically meaningful findings in Columbia Suicide Severity Rating Scale (C-SSRS) Responses

    Time frame: From ICF signing date to Day 15.

  9. Time to reach maximum plasma concentration (Tmax) of HRS-2129

    Time frame: 0 hour to 216 hours after administration.

  10. Terminal half-life (t1/2)

    Time frame: 0 hour to 216 hours after administration.

  11. Maximum plasma concentration (Cmax) of HRS-2129

    Time frame: 0 hour to 216 hours after administration.

  12. Apparent clearance (CL/F) of HRS-2129

    Time frame: 0 hour to 216 hours after administration.

  13. Apparent volume of distribution (Vz/F) of HRS-2129

    Time frame: 0 hour to 216 hours after administration.

07

Study locations

1 site
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410013, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Jul 2025, 6 months.

Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's 6 months is above that.

Counting every sponsor, half of 220 studies reached it within 9 months; a quarter within 3 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2024
First posted
Dec 19, 2024
StartActual
Dec 30, 2024
Primary completionActual
Jul 2, 2025
CompletionActual
Jul 2, 2025
Last update
Sep 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06742840
Responsible party
Sponsor
First posted
Dec 19, 2024
Start date
Dec 30, 2024
Primary completion
Jul 2, 2025
Completion
Jul 2, 2025
Last update
Sep 3, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-2129

Start the discussion